1. Home
  2. GBDC vs LQDA Comparison

GBDC vs LQDA Comparison

Compare GBDC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Golub Capital BDC Inc.

GBDC

Golub Capital BDC Inc.

HOLD

Current Price

$12.72

Market Cap

3.5B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$40.19

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBDC
LQDA
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.1B
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
GBDC
LQDA
Price
$12.72
$40.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
10
Target Price
$14.17
$38.60
AVG Volume (30 Days)
2.5M
1.9M
Earning Date
02-04-2026
03-18-2026
Dividend Yield
12.12%
N/A
EPS Growth
N/A
N/A
EPS
1.24
N/A
Revenue
$857,084,000.00
$69,216,000.00
Revenue This Year
N/A
$993.31
Revenue Next Year
N/A
$219.14
P/E Ratio
$10.35
N/A
Revenue Growth
9.80
343.41
52 Week Low
$12.28
$11.26
52 Week High
$16.01
$46.67

Technical Indicators

Market Signals
Indicator
GBDC
LQDA
Relative Strength Index (RSI) 38.35 49.95
Support Level $12.36 $41.34
Resistance Level $12.98 $46.67
Average True Range (ATR) 0.28 2.53
MACD -0.07 -0.56
Stochastic Oscillator 28.81 17.08

Price Performance

Historical Comparison
GBDC
LQDA

About GBDC Golub Capital BDC Inc.

Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: